<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03212196</url>
  </required_header>
  <id_info>
    <org_study_id>PREP 1041CESC</org_study_id>
    <nct_id>NCT03212196</nct_id>
  </id_info>
  <brief_title>Technical Strategies for Pancreatic Fistula Prevention After Pancreaticoduodenectomy in High-risk Pancreatic Remnant</brief_title>
  <acronym>PREP</acronym>
  <official_title>Technical Strategies for Pancreatic Fistula Prevention After Pancreaticoduodenectomy in High-risk Pancreatic Remnant: a Risk-adjusted Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria Integrata Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria Integrata Verona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will investigate what surgical technique between pancreaticogastrostomy and
      pancreaticojejunostomy with transanastomotic externalized drains is associated with the
      lowest rate of pancreatic fistula after pancreaticoduodenectomy in case of high-risk
      pancreatic remnants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic fistula is the major determinant of outcome after pancreaticoduodenectomy. Several
      strategies to reduce the burden of this complication have been proposed in the last decade. A
      definite answer about what is the best technique to approach a high-risk pancreatic stump is
      still needed. Both pancreaticogastrostomy and pancreaticojejunostomy with transanastomotic
      externalized drains have been proposed in this setting, but often studies do not provide a
      reliable risk stratification and result are extremely variable.

      The aim of this trial is to evaluate what surgical technique, between pancreaticogastrostomy
      and pancreaticojejunostomy with transanastomotic externalized drains, is associated with the
      lowest rate of pancreatic fistula in case of high-risk pancreatic remnants. Risk
      stratification will be provided through the Fistula Risk Score, a clinical risk score that
      has been extensively validated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative Pancreatic Fistula (POPF)</measure>
    <time_frame>30 days post-operative</time_frame>
    <description>Presence of Amylase &gt; 3 times the upper limit of normal in surgical drains at or by post-operative day 3 (POD) determining a clinically relevant change in patient's management</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>POPF severity</measure>
    <time_frame>30 days post-operative</time_frame>
    <description>POPF grade B and grade C rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>1 year</time_frame>
    <description>calculated from the day of surgery to the day of discharge, adding up the days after a possible re-admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Death related to surgical morbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Pancreatectomy Hemorrhage</measure>
    <time_frame>90 days</time_frame>
    <description>As defined by the International Study Group for Pancreatic Surgery (ISGPS), grade A, B and C rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed Gastric Emptying</measure>
    <time_frame>90 days</time_frame>
    <description>As defined by ISGPS, grade A, B and C rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biliary fistula</measure>
    <time_frame>90 days</time_frame>
    <description>Output of bile from drains on or by POD 3, pancreaticojejunostomy leak should be ruled out</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrojejunal/Duodenojejunal fistula</measure>
    <time_frame>90 days</time_frame>
    <description>Fistula from gastro/duodenojejunostomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal abscess</measure>
    <time_frame>90 days</time_frame>
    <description>Collection &gt;5cm in size, containing gas bubbles, determining systemic signs of infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute pancreatitis</measure>
    <time_frame>1 day post index surgery</time_frame>
    <description>Altered serum amylase count on POD 0 or POD 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound infection</measure>
    <time_frame>90 days</time_frame>
    <description>Superficial and Deep Surgical Site Incisional Infection as defined by the Center for Disease Control and Prevention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusions</measure>
    <time_frame>90 days</time_frame>
    <description>Need and number of packed red blood cells transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>90 days</time_frame>
    <description>Myocardial necrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Kidney Failure</measure>
    <time_frame>90 days</time_frame>
    <description>Abrupt change in serum creatinine &gt;1.5 baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Embolism</measure>
    <time_frame>90 days</time_frame>
    <description>Blood clots in the pulmonary arterial system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumonia</measure>
    <time_frame>90 days</time_frame>
    <description>Bacterial infection of the lungs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory insufficiency</measure>
    <time_frame>90 days</time_frame>
    <description>Need for re-intubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Tract Infection</measure>
    <time_frame>90 days</time_frame>
    <description>Bacterial infection of the urinary tract</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular accidents</measure>
    <time_frame>90 days</time_frame>
    <description>Stroke, hemorrhage, brain death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation</measure>
    <time_frame>90 days</time_frame>
    <description>Need for new surgery due to severe morbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission</measure>
    <time_frame>30 days after hospital discharge</time_frame>
    <description>New admission within 30-days of discharge from hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-adjuvant therapy</measure>
    <time_frame>1 year</time_frame>
    <description>Time form index operation to the beginning of adjuvant treatment (only for malignancy)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Pancreatic Fistula</condition>
  <arm_group>
    <arm_group_label>Pancreaticogastrostomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pancreaticogastrostomy with external drain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreaticojejunostomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pancreaticojejunostomy with transanastomotic drain</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pancreaticogastrostomy with external drain</intervention_name>
    <description>Pancreatico-enteric anastomosis is provided according to the &quot;Bassi technique&quot;, pancreatic remnant is pushed into the gastric cavity through a posterior gastrotomy. An externalized drain is placed into the main pancreatic duct.</description>
    <arm_group_label>Pancreaticogastrostomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pancreaticojejunostomy with transanastomotic drain</intervention_name>
    <description>Pancreatico-enteric anastomosis is provided through a double-layer, duct-to-mucosa anastomosis with a transanastomotic externalized drain.</description>
    <arm_group_label>Pancreaticojejunostomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All the patients undergoing pancreaticoduodenectomy (only Whipple or Traverso) for all
             kind of pancreatic disease (benign, malignant or premalignant).

          -  Patients able to give their informed consent

        Exclusion criteria

          -  Informed consent withdrawal

          -  Impossibility to undergo surgery for any reason

          -  Use of glues or biological matrices to protect the anastomosis

          -  Fistula Risk Score &lt; 7

          -  Post-operative octreotide analogues administration (only prophylactic use, therapeutic
             use allowed)

          -  Wrong randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Bassi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universit√† degli Studi di Verona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano Andrianello, MD</last_name>
    <phone>0458124553</phone>
    <phone_ext>0039</phone_ext>
    <email>stefano.andrianello@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erica Secchettin</last_name>
    <phone>0458124553</phone>
    <email>erica.secchettin@aovr.veneto.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale Policlinico GB Rossi</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Marchegiani, MD</last_name>
      <phone>0458124553</phone>
      <phone_ext>0039</phone_ext>
      <email>giovanni.marchegiani@univr.it</email>
    </contact>
    <investigator>
      <last_name>Claudio Bassi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>McMillan MT, Ecker BL, Behrman SW, Callery MP, Christein JD, Drebin JA, Fraker DL, Kent TS, Lee MK, Roses RE, Sprys MH, Vollmer CM Jr. Externalized Stents for Pancreatoduodenectomy Provide Value Only in High-Risk Scenarios. J Gastrointest Surg. 2016 Dec;20(12):2052-2062. Epub 2016 Oct 11.</citation>
    <PMID>27730401</PMID>
  </reference>
  <reference>
    <citation>Bassi C, Molinari E, Malleo G, Crippa S, Butturini G, Salvia R, Talamini G, Pederzoli P. Early versus late drain removal after standard pancreatic resections: results of a prospective randomized trial. Ann Surg. 2010 Aug;252(2):207-14. doi: 10.1097/SLA.0b013e3181e61e88.</citation>
    <PMID>20622661</PMID>
  </reference>
  <reference>
    <citation>Callery MP, Pratt WB, Kent TS, Chaikof EL, Vollmer CM Jr. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. J Am Coll Surg. 2013 Jan;216(1):1-14. doi: 10.1016/j.jamcollsurg.2012.09.002. Epub 2012 Nov 2.</citation>
    <PMID>23122535</PMID>
  </reference>
  <reference>
    <citation>Hallet J, Zih FS, Deobald RG, Scheer AS, Law CH, Coburn NG, Karanicolas PJ. The impact of pancreaticojejunostomy versus pancreaticogastrostomy reconstruction on pancreatic fistula after pancreaticoduodenectomy: meta-analysis of randomized controlled trials. HPB (Oxford). 2015 Feb;17(2):113-22. doi: 10.1111/hpb.12299. Epub 2014 Jul 7.</citation>
    <PMID>25040921</PMID>
  </reference>
  <reference>
    <citation>Wang SE, Chen SC, Shyr BU, Shyr YM. Comparison of Modified Blumgart pancreaticojejunostomy and pancreaticogastrostomy after pancreaticoduodenectomy. HPB (Oxford). 2016 Mar;18(3):229-35. doi: 10.1016/j.hpb.2015.09.007. Epub 2015 Nov 17.</citation>
    <PMID>27017162</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreaticoduodenectomy</keyword>
  <keyword>Pancreaticogastrostomy</keyword>
  <keyword>Pancreaticojejunostomy</keyword>
  <keyword>Stent</keyword>
  <keyword>Transanastomotic drain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Pancreatic Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Participant Data will not be shared with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

